[1]
|
National Academy of Sciences (2000) Dietary reference intakes for Vitamin C, Vitamin E, selenium and carotenoids. National Academy Press, Washington DC.
|
[2]
|
Bjorneboe, A., Bjorneboe, G. and Drevon, C. (1990) Absorption, transport and distribution of Vitamin E. Journal of Nutrition, 120, 233-242.
|
[3]
|
Ford, E.S. and Sowell, A. (1999) Serum Alpha-tocopherol status in the United States population: Findings from the third national health and nutrition examination survey. American Journal of Epidemiology, 150, 290-300. doi:10.1093/oxfordjournals.aje.a010001
|
[4]
|
Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373.
|
[5]
|
Aparicio, J.M., et al. (2001) Ataxia with isolated Vitamin E deficiency: Case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition, 33, 206-210. doi:10.1097/00005176-200108000-00022
|
[6]
|
Sokol, R.J., et al. (1985) Vitamin E deficiency in adults with chronic liver disease. The American Journal of Clinical Nutrition, 41, 66-72.
|
[7]
|
Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373.
doi:10.1146/annurev.nu.08.070188.002031
|
[8]
|
Victor, M. and Ropper, A.H. (2005) Disorders due to deficiencies of fat-soluble Vitamins. 7th Edition, McGraw-Hill, New York.
|
[9]
|
Ziegner, U.H., et al. (2002) Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clinical Immunology, 102, 19-24.
doi:10.1006/clim.2001.5140
|
[10]
|
Aslam, A., Misbah, S.A., Talbot, K. and Chapela, H. (2004) Vitamin E deficiency induced neurological disease in common variable immunodeficiency: Two cases and a review of the literature of Vitamin E deficiency. Clinical Immunology, 112, 24-29.
doi:10.1016/j.clim.2004.02.001
|
[11]
|
Sokol, R.J. (1988) Vitamin E deficiency and neurologic disease. Annual Review of Nutrition, 8, 351-373.
doi:10.1146/annurev.nu.08.070188.002031
|
[12]
|
Weber, P., Bendich, A. and Machlin, L.J. (1997) Vitamin E and human health: Rationale for determining recommended intake levels. Nutrition, 13, 450-460.
doi:10.1016/S0899-9007(97)00110-X
|
[13]
|
Kappus, H. and Diplock, A.T. (1992) Tolerance and safety of Vitamin E: A toxicological position report. Free Radical Biology & Medicine, 13, 55-74.
doi:10.1016/0891-5849(92)90166-E
|
[14]
|
Ricciarelli, R., Argellati, F., Pronzato, M.A., et al. (2007) Vitamin E and neurodegenerative diseases. Molecular Aspects of Medicine 28, 591-606.
doi:10.1016/j.mam.2007.01.004
|
[15]
|
Practice Guidelines Cover (1997) Management of Alzheimer’s disease. American Journal of Health-System Pharmacy, 54, 1481-1485.
|
[16]
|
Grundman, M. (2000) Vitamin E and alzheimer disease: The basis for additional clinical trials. The American Journal of Clinical Nutrition, 71, S630- S636.
|
[17]
|
Weber, C.A. and Ernst, M.E. (2006) Antioxidants, sup- plements, and Parkinson’s disease. The Annals of Pharmacotherapy, 40, 935-938. doi:10.1345/aph.1G551
|
[18]
|
Parkinson Study Group (1989) Datatop: A multicenter controlled clinical trial in early Parkinson’s disease. Archives of Neurology, 46, 1052-1060.
doi:10.1001/archneur.1989.00520460028009
|
[19]
|
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The New England Journal of Medicine, 328, 176-183. doi:10.1056/NEJM199301213280305
|
[20]
|
Ricciarelli, R., Argellati, F. and Cinzia Domenicotti, M.A. (2007) Vitamin E and neurodegenerative diseases: Review. Molecular Aspects of Medicine, 28, 591-606.
doi:10.1016/j.mam.2007.01.004
|
[21]
|
Graf, M., et al. (2005) High dose Vitamin E therapy in amyotrophic laterals sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. Journal of Neural Transmission, 112, 649-660.
doi:10.1007/s00702-004-0220-1
|
[22]
|
Nelson, L.M., Matkin, C., Longstreth, Jr., et al. (2000) Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. American Journal of Epidemiology, 151, 164-173.
doi:10.1093/oxfordjournals.aje.a010184
|
[23]
|
Aparicio, J.M., Quintana, A.B., Suárez, L., et al., (2001) Ataxia with isolated Vitamin E deficiency: Case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition, 33, 206-210.
doi:10.1097/00005176-200108000-00022
|
[24]
|
Benomar, A., Yahyaoui, M., Meggouh, F., et al., (2002) Clinical comparison between AVED patients with (744 Del A) mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. Journal of the Neurological Sciences, 198, 25-29.
doi:10.1016/S0022-510X(02)00057-6
|
[25]
|
Marzouki, N., Benomar, A., Yahyaoui, M., et al., (2005) Vitamin E deficiency ataxia with (744 Del A) mutation on a-TTP gene: Genetic and clinical peculiarities in Moroccan patients. European Journal of Medical Genetics, 48, 21-28. doi:10.1016/j.ejmg.2005.01.014
|
[26]
|
Schurks, M., Glynn, R.J., Rist, P.M., et al., (2010) Effects of Vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. British Medical Journal, 341, 1-8. doi:10.1136/bmj.c5702
|
[27]
|
Argyriou, A.A., Chroni, E., Koutras, A., et al., (2006) Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of Vitamin E supplementation. Journal of Pain and Symptom Management. 3, 237-244.
doi:10.1016/j.jpainsymman.2006.03.013
|
[28]
|
Pace, A., Giannarelli, D., Galiè, E., et al., (2010) Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology, 74, 762-766.
doi:10.1212/WNL.0b013e3181d5279e
|